More on BHC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $6.31 |
|
|||
| Open | $6.31 | ||||
| 52 Wk High | $4.75 | ||||
| 52 Wk Low | $4.75 | ||||
| Day High | $6.31 | ||||
| Day Low | $6.31 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,985 | ||||
- Form 8-K Bausch & Lomb Corp For: Oct 11
- Bausch Health study shows modest gains in cirrhosis care adherence
- Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
- Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
- RBC Capital Reiterates Sector Perform Rating on Bausch Health Companies (BHC)
- Bausch + Lomb eyes 2027 trial start for oral dry AMD drug
- Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
- Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
- Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
- Form 4 Bausch Health Companies For: Sep 30 Filed by: Paulson John
Entities mentioned with BHC
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Definitive Agreement | View Related Stories »
- IPO | View Related Stories »
- Show More...
